## **Trustees’ Annual Report for the period** 

**From** 10/10/2023 to 05/04/2025 

**Charity name:** The Immuno Oncology Clinical Network (IOCN) 

**Charity registration number:** 1205140 

## **Objectives and Activities** 

The main purposes of the Immuno-Oncology Clinical Network are to promote and protect the health of the public, and particularly those undergoing immuno-oncology therapies, by: 

- Providing education and advice to health care professionals involved in the delivery of such therapies. 

- Promote and support research (provided that the useful results of such research will be published or disseminated) or other similar activities which will advance knowledge and understanding of immuno-oncology treatments and the associated side effects 

The charity’s main activities are the provision of education and training, clinical support, providing guidance on immuno-oncology policy and governance, and support for healthcare professionals developing immuno-oncology services. 

The trustees confirm that they have had due regard to the guidance issued by the Charity Commission on public benefit. In particular, the trustees have considered how the charity’s activities further its charitable purposes for the public benefit. The trustees believe that the charity has complied with the duty in section 17 of the Charities Act 2011 to have regard to the Charity Commission’s guidance on public benefit when exercising their powers and duties. 

The IOCN recognises the contribution of 25 volunteers who supported the delivery of its educational programme, including online webinars and one in-person event. In addition, 20 volunteers contributed to the charity’s education and policy and governance pillar. 

The IOCN does not make grants to individuals or organisations and does not provide funding to other charities. 

## **Achievements and Performance** 

During the reporting period the IOCNs main charitable achievements included: 

- The charity delivered free monthly educational webinars for healthcare professionals on immuno-oncology treatments and the management of associated side effects, including the _Ask a Question_ and _New and Novel_ webinar series. 



- The charity provided in-person education on immuno-oncology treatments, including the _Case Conundrums_ event held in March 2025 and a number of collaborative events delivered in partnership with SBK Healthcare Events. 

- The charity supported the development of consensus statements to promote good practice, including the _Baseline Cardiac Biomarkers Statement_ produced in collaboration with the British Cardio-Oncology Society (BCOS). 

- The charity developed patient information including a leaflet on checkpoint inhibitors to support patients’ understanding of treatment logistics, practical considerations, and potential immune-mediated side effects. 

- In collaboration with the British Oncology Pharmacy Association (BOPA), the charity contributed to the publication of immunosuppressant monographs providing guidance on their prescribing and monitoring for the management of immune-related adverse events associated with immune checkpoint inhibitor therapy. 

- The Charity developed the IOCN website as a single, accessible resource for healthcare professionals, providing clinical guidelines, patient information and resources, and network contact details. 

These activities directly support the charity’s objectives by improving clinical knowledge, promoting safe delivery of immuno-oncology treatments, and supporting healthcare professionals, thereby benefiting patients receiving such therapies. 

## **Future plans:** 

In the next reporting period, the charity plans to expand its educational programme, continue the development of clinical guidance, produce additional patient information resources, address key policy and governance issues affecting healthcare professionals managing patients receiving immuno-oncology treatments, and further support healthcare professionals in the development of immuno-oncology services. 

## **Financial Review** 

## **Income and Expenditure** 

- **Total incoming resources:** £55,928 

- **Total resources expended:** £21,100 

The trustees consider that maintaining reserves equivalent to 4-6 months of core operating costs is appropriate to ensure financial stability and continuity of services in the event of funding delays or unexpected expenditure. This equates for a minimum of £5000. The charity held no restricted funds at the reporting date and there were no funds in material deficit. 

The trustees have considered the charity’s financial position and future funding. They have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future, and accordingly the accounts have been prepared on a going concern basis. The trustees are not aware of any material uncertainties that may cast significant doubt on the charity’s ability to continue as a going concern. 

## **Funding sources:** 



The IOCN’s funding sources include sponsorship (both restricted and unrestricted), grants, and donations from pharmaceutical and biotechnology companies committed to improving outcomes for cancer patients receiving immuno-oncology treatments. The trustees have appropriate policies in place to manage conflicts of interest and to ensure the charity’s independence in its educational and clinical activities. 

In addition, the IOCN generates income from registration fees paid by delegates attending its in-person educational events. 

## **Risk assessment:** 

The trustees have identified and reviewed the principal risks facing the charity and have implemented appropriate controls and policies to mitigate those risks. The principal risks identified are: 

1. **Financial sustainability** – The charity is currently largely dependent on pharmaceutical industry funding, which could affect its ability to continue delivering activities if income were reduced or delayed. This risk is mitigated through regular financial monitoring, the maintenance of appropriate reserves, and efforts to diversify income sources, including seeking funding from biotechnology companies and exploring membership options for educational activities. 

2. **Dependence on key individuals and volunteers** – The charity relies on a small number of trustees, volunteers, and senior personnel with specialist expertise. The trustees mitigate this risk through succession planning, active trustee recruitment, and clear role descriptions and procedures. The charity has planned a step-by-step approach to additional volunteer recruitment in order to increase volunteer numbers while supporting sustainable growth. 

## **Structure, Governance and Management** 

The IOCN is a Charitable Incorporated Organisation (CIO) governed by a single constitution and does not hold or administer any separate trusts. 

The Charity selects Trustees in accordance with its ‘Appointment of New Trustees’ policy. The IOCN appoints trustees to fill vacancies or strengthen the board’s skills and experience, following an agreed and transparent recruitment process. The Trustees will either advertise a trustee position openly or a candidate can be nominated by the other trustees or by another organisation. Trustees are appointed following appropriate vetting, conflict-ofinterest checks, and an induction process. 

The charity is run by a small voluntary executive team comprising the Chief Executive Officer, Deputy Chief Executive Officer and Operations Director. The executive team oversees the day-to-day running of the charity and its paid administrators. 



## **Reference and Administrative details** 

|Charity name|The Immuno-Oncology Clinical Network|
|---|---|
|Other name the charity uses|The IOCN|
|Registered charity number|1205140|
|Charity’s principal address|IO Clinical Network<br>PO BOX 303, Liverpool<br>L22 2AA|
|||





**Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**<br>**year**|**Name of person (or body) entitled**<br>**to appoint trustee (ifany)**|
|---|---|---|---|---|
||Anna Olsson-Brown||Oct 2023 –present||
||Alexandra Johnson||Oct 2023 –present||
||RickyFrazer||Oct 2023 –present||
||Clare Barlow||Oct 2023 –present||
||Alice Tew||Feb 2025-present||
||Brent O’Carrigan||Oct 2023 –present||
||Alison Hodge||Feb 2025-present||
||TrudyGuinan||Oct 2023 –present||
||Kate Young||Oct 2023 –present||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||



## – Corporate trustees names of the directors at the date the report was approved 

## **Director name** 

Name of trustees holding title to property belonging to the charity 

**Trustee name Dates acted if not for whole year** 



## **Funds held as custodian trustees on behalf of others** 

Description of the assets No funds or objects of the charity are held by trustees. held in this capacity 

Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity’s objects 

Details of arrangements for safe custody and segregation of such assets from the charity’s own assets 

## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

**Type of Name Address adviser** 

## **Name of chief executive or names of senior staff members (Optional information)** 

## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

## **Other optional information** 



## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

**Signature(s) Full name(s)** Dr Alexandra Diana Johnson 

**Position (eg Secretary,** Trustee **Chair, etc)** 

**Date** 30/1/26 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

**REGISTERED CHARITY NUMBER: 1205140** 

**Report of the Trustees and Unaudited Financial Statements for the Year Ended 30 April 2025** 

**for** 

**Immuno-Oncology Clinical Network** 

Bennett Brooks & Co Ltd Chartered Accountants Cherry Tree Court Cross Street Leek Staffordshire ST13 6BL 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

**Immuno-Oncology Clinical Network** 

## **Contents of the Financial Statements for the year ended 30 April 2025** 

|||**Page**||
|---|---|---|---|
|**Report of the Trustees**||1||
|**Independent Examiner's Report**||2||
|**Statement of Financial Activities**||3||
|**Balance Sheet**||4||
|**Notes to the Financial Statements**|5|to|6|
|**Detailed Statement of Financial Activities**||7||





�������������������� ��� � ����� � ���  ���� �  �  � ����� 

## **Immuno-Oncology Clinical Network** 

## **Report of the Trustees for the year ended 30 April 2025** 

The trustees present their report with the financial statements of the charity for the year ended 30 April 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document** 

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity. 

## **REFERENCE AND ADMINISTRATIVE DETAILS** 

## **Registered Charity number** 

1205140 

**Principal address** PO Box 303 Liverpool L22 2AA 

**Trustees** Ms A C Olsson-Brown Dr A Johnson Miss T Guinan Mrs A Tew Dr K Young Dr R Frazer Miss A Hodge Dr C Barlow 

**Independent Examiner** Bennett Brooks & Co Ltd Chartered Accountants Cherry Tree Court Cross Street Leek Staffordshire ST13 6BL 

���������� Approved by order of the board of trustees on ............................................. and signed on its behalf by: 


.............................................................................. Ms A C Olsson-Brown - Trustee 

Page 1 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

## **Independent Examiner's Report to the Trustees of Immuno-Oncology Clinical Network** 

## **Independent examiner's report to the trustees of Immuno-Oncology Clinical Network** 

I report to the charity trustees on my examination of the accounts of Immuno-Oncology Clinical Network (the Trust) for the year ended 30 April 2025. 

## **Responsibilities and basis of report** 

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of  the Charities Act 2011 ('the Act'). 

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act. 

## **Independent examiner's statement** 

I have completed my examination. I confirm that no material matters have come to my attention in connection with the  examination giving me cause to believe that in any material respect: 

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or 

2. the accounts do not accord with those records; or 

3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination. 

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. 


Mrs C Hambleton 

Bennett Brooks & Co Ltd Chartered Accountants Cherry Tree Court Cross Street Leek Staffordshire ST13 6BL � �������� Date: ............................................. 

Page 2 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

||**Immuno-Oncology Clinical Network**||
|---|---|---|
||**Statement of Financial Activities**||
||**for the year ended 30 April 2025**||
|||Unrestricted|
|||fund|
||Notes|£|
|**INCOME AND ENDOWMENTS FROM**|||
|Donations and legacies||55,928|
|**EXPENDITURE ON**|||
|Raising funds|2|21,036|
|Other||64|
|**Total**||21,100|
|**NET INCOME**||34,828|
|**TOTAL FUNDS CARRIED FORWARD**||34,828|
||||



The notes form part of these financial statements 

Page 3 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

## **Immuno-Oncology Clinical Network** 

|||**Balance Sheet**|||
|---|---|---|---|---|
|||**30 April 2025**|||
|||||Unrestricted|
|||||fund|
|Notes||||£|
|**FIXED ASSETS**|||||
|Tangible assets|4|||256|
|**CURRENT ASSETS**|||||
|Cash at bank||||35,052|
|**CREDITORS**|||||
|Amounts falling due within one year|5|||(480)|
|**NET CURRENT ASSETS**||||34,572|
|**TOTAL ASSETS LESS CURRENT LIABILITIES**||||34,828|
|**NET ASSETS**||||34,828|
|**FUNDS**|6||||
|Unrestricted funds||||34,828|
|**TOTAL FUNDS**||||34,828|
||||����������||



The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by: 


............................................. A C Olsson-Brown - Trustee 

The notes form part of these financial statements 

Page 4 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

## **Immuno-Oncology Clinical Network** 

## **Notes to the Financial Statements for the year ended 30 April 2025** 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention. 

## **Income** 

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the  obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

## **Tangible fixed assets** 

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. 

- Fixtures and fittings - 20% on reducing balance 

## **Taxation** 

The charity is exempt from tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. 

## **2. RAISING FUNDS** 

## **Raising donations and legacies** 

||£|
|---|---|
|Support costs|(6,412)|



## **3. TRUSTEES' REMUNERATION AND BENEFITS** 

There were no trustees' remuneration or other benefits for the year ended 30 April 2025. 

## **Trustees' expenses** 

There were no  trustees' expenses paid for the year ended 30 April 2025. 

continued... 

Page 5 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

## **Immuno-Oncology Clinical Network** 

## **Notes to the Financial Statements - continued for the year ended 30 April 2025** 

## **4. TANGIBLE FIXED ASSETS** 


**----- Start of picture text -----**<br>
|||||
|---|---|---|---|
|Fixtures|
|and|
|fittings|
|£|
|COST|
|Additions|320|
|DEPRECIATION|
|Charge for year|64|
|NET BOOK VALUE|
|At 30 April 2025|256|
|CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR|
|£|
|Other creditors|480|
|MOVEMENT IN FUNDS|
|Net|
|movement|
|in funds|At 30.4.25|
|£|£|
|Unrestricted funds|
|General fund|34,828|34,828|
|TOTAL FUNDS|34,828|34,828|
|Net movement in funds, included in the above are as follows:|
|Incoming|Resources|Movement|
|resources|expended|in funds|
|£|£|£|
|Unrestricted funds|
|General fund|55,928|(21,100)|34,828|
|TOTAL FUNDS|55,928|(21,100)|34,828|

**----- End of picture text -----**<br>


## **5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

## **6. MOVEMENT IN FUNDS** 

## **7. RELATED PARTY DISCLOSURES** 

There were no related party transactions for the year ended 30 April 2025. 

Page 6 



�������������������� ��� � ����� � ���  ���� �  �  � ����� 

## **Immuno-Oncology Clinical Network** 

## **Detailed Statement of Financial Activities for the year ended 30 April 2025** 

|**INCOME AND ENDOWMENTS**<br>**Donations and legacies**<br>Grants<br>Subscriptions<br>Donated services and facilities<br>**Total incoming resources**<br>**EXPENDITURE**<br>**Other trading activities**<br>Purchases<br>**Other**<br>Fixtures and fittings<br>**Support costs**<br>**Management**<br>Professional services<br>Postage and stationery<br>Advertising<br>Sundries<br>Travel expenses<br>No description<br>**Information technology**<br>Repairs and renewals<br>**Governance costs**<br>Accountancy and legal fees<br>Total resources expended<br>**Net income**|£<br>10,000<br>1<br>45,927<br>55,928<br>55,928<br>4,664<br>64<br>3,673<br>1,183<br>5,265<br>3,085<br>1,329<br>621<br>15,156<br>736<br>480<br>21,100<br>34,828|
|---|---|



This page does not form part of the statutory financial statements 

Page 7